Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia

NCT04364269 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-Thalassemia
Non-transfusion-dependent Thalassemia

Interventions

DRUG: VIT-2763 once a day (QD)
DRUG: VIT-2763 twice a day (BID)
DRUG: Placebo

Sponsor

Vifor (International) Inc.

Collaborators

[object Object]